unresectable advanced hepatocellular carcinoma
Conditions
Interventions
None listed
Sponsors
Nagoya University Graduate School of Medicine
Ogaki Municipal Hospital Kariya Toyota general hospital Tosei General Hospital Toyohashi Municipal Hospital Fujita Health University National Center for Global Health and Medicine
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Clinically diagnosed as HCC No indication for local treatment such as liver resection, liver transplantation, or radiofrequency ablation Having a treatable liver function Performance status of 0-2 on ECOG Age is 20 years or older.
Exclusion criteria
Exclusion criteria: Patients who wish to be excluded from the study. Patients who are pregnant, or lactating, may become pregnant, intend to become pregnant, or who wish to have a baby. Patients with the following serious complications: 1. Cardiovascular abnormalities such as heart failure, angina pectoris, or arrhythmia are difficult to control even after treatment. 2. Myocardial infarction within 6 months of onset 3. Renal failure 4. Active infectious disease except for viral hepatitis 5. Active gastrointestinal bleeding 6. Other active cancer requiring treatment 7. Hepatic encephalopathy or severe mental disorder 8. Severe drug allergy 9. Serious autoimmune disease. Other conditions that the physician deems inappropriate for the safe conduct of this study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Investigating the biomarkers, including cytokine and chemokine at pretreatment, 1,3,6 week after treatment, on adverse events, including immune-related liver injury | — |
Secondary
| Measure | Time frame |
|---|---|
| Investigating the biomarkers, including cytokine and chemokine at pretreatment, 1,3,6 week after treatment, on the therapeutic effects and prognosis | — |
Countries
Japan
Contacts
Public ContactTakanori Ito
Nagoya University Hospital Gastroenterology and Hepatology
Outcome results
None listed